Comparative Pharmacology
Head-to-head clinical analysis: RELA versus TRANCOPAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RELA versus TRANCOPAL.
RELA vs TRANCOPAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
Trancopal (chlormezanone) is a centrally acting muscle relaxant and anxiolytic. Its exact mechanism is not fully understood, but it is believed to act on the central nervous system by depressing polysynaptic reflexes and possibly through GABAergic modulation.
Adults: 250-350 mg orally 3-4 times daily.
200-400 mg orally every 6 hours as needed for acute musculoskeletal pain; maximum 1.6 g per day.
None Documented
None Documented
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Terminal elimination half-life: 20-30 hours in healthy adults. Prolonged in hepatic impairment (up to 60 hours).
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Primarily renal: ~95% as metabolites (glucuronides, sulfate conjugates) with <1% unchanged. Fecal: <5%.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant